<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841020</url>
  </required_header>
  <id_info>
    <org_study_id>19081</org_study_id>
    <nct_id>NCT02841020</nct_id>
  </id_info>
  <brief_title>The Effect of Pre-treatment Biopsy for Non-neoplastic Renal Disease vs no Biopsy on Estimated Glomerular Filtration Rate in Patients With Small Renal Mass: a Single-center, Single-blinded, Randomized, Parallel Group Clinical Trial</brief_title>
  <official_title>The Effect of Pre-treatment Biopsy for Non-neoplastic Renal Disease vs no Biopsy on Estimated Glomerular Filtration Rate in Patients With Small Renal Mass: a Single-center, Single-blinded, Randomized, Parallel Group Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if biopsy for non-neoplastic renal disease for
      patients with a small renal mass results in greater postoperative renal function than the
      current standard of care (no additional biopsy).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding for study fell through
  </why_stopped>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference in change in glomerular filtration rate (GFR)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Kidney Neoplasms</condition>
  <arm_group>
    <arm_group_label>Control SOC</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care is followed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental additional biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Additional biopsy</intervention_name>
    <description>â€¢ Patients in the experimental group receive the additional biopsy for non-neoplastic disease during the same procedure before the biopsy of the renal mass (with potential for direct benefit to the patient by revealing non-neoplastic renal disease).</description>
    <arm_group_label>Experimental additional biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or greater

          -  Scheduled for renal biopsy as part of clinical care

          -  Diagnosis of small renal mass (&lt; 4cm) based on imaging (CT, MRI, Ultrasound, or other)

          -  Patient must provide written, informed consent for study procedures before
             randomization

          -  Renal mass must be primarily solid (as opposed to cystic) in nature

        Exclusion Criteria:

          -  Patients less than 18 years of age

          -  Patients who are prisoners

          -  Women who are pregnant-self reported

          -  Patients with Bosniak 3 or 4 cystic renal masses

          -  Patients with history of renal transplantation

          -  Patients with eGFR less than 30-based on review of clinical labs

          -  Patients on dialysis

          -  Patients with bleeding disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>October 26, 2018</last_update_submitted>
  <last_update_submitted_qc>October 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Noah Schenkman, MD</investigator_full_name>
    <investigator_title>Associate Professor of Urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

